Cloud-clone
SKU(재고 관리 코드):LML643Hu
Magnetic Luminex Assay Kit for EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc.
Magnetic Luminex Assay Kit for EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc.
Product No.
LML643Hu
Organism Species
Homo sapiens (Human).
Sample Type
Serum, plasma, tissue homogenates and other biological fluids
Test Method
Double-antibody Sandwich
Assay Length
3.5h
Detection Range
1.95-2000pg/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 0.65 pg/mL.
UOM
1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex
Specificity
This assay has high sensitivity and excellent specificity for detection of EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc..
No significant cross-reactivity or interference between EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 83-105 | 96 |
| EDTA plasma(n=5) | 96-104 | 101 |
| heparin plasma(n=5) | 97-105 | 102 |
| sodium citrate plasma(n=5) | 87-103 | 97 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 90-99% | 80-97% | 80-99% | 81-90% |
| EDTA plasma(n=5) | 93-105% | 79-104% | 96-105% | 96-105% |
| heparin plasma(n=5) | 88-97% | 80-101% | 85-101% | 92-101% |
| sodium citrate plasma(n=5) | 87-96% | 79-96% | 94-103% | 94-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:EGFL7) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
| Magazine | Citations |
| Scientific Reports | Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab PMC5443778 |
| Scientific Reports | Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. pubmed:28539619 |
| International Journal of Clinical and Experimental Pathology | EGF like domain multiple 7 regulates the migration and invasion of prostate cancer cells ISSN:1936-2625 |
| Cancer Drug Resist | MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy |
| Catalog No. | Related products for research use of Homo sapiens (Human) Organism species | Applications (RESEARCH USE ONLY!) |
| RPL643Hu01 | Recombinant EGF Like Domain Protein, Multiple 7 (EGFL7) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAL643Hu01 | Polyclonal Antibody to EGF Like Domain Protein, Multiple 7 (EGFL7) | WB; IHC; ICC; IP. |
| MAL643Hu21 | Monoclonal Antibody to EGF Like Domain Protein, Multiple 7 (EGFL7) | WB; IHC; ICC; IP. |
| SEL643Hu | ELISA Kit for EGF Like Domain Protein, Multiple 7 (EGFL7) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LML643Hu | Magnetic Luminex Assay Kit for EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. | Magnetic Luminex Assay for Antigen Detection. |
| PGL643Hu01 | Primer Pair for EGF Like Domain Protein, Multiple 7 (EGFL7) | PCR |
Share
